Prescrire Int. 2007 Oct;16(91):194.
When treatment for ulcerative colitis with steroids and immunosuppressants is ineffective or poorly tolerated, two placebo-controlled trials have demonstrated that infliximab yields remissions permitting steroid withdrawal in about 20% of patients. However, the long-term risks of infections and cancer mean that infliximab should be reserved for the most severely ill patients.
当使用类固醇和免疫抑制剂治疗溃疡性结肠炎无效或耐受性差时，两项安慰剂对照试验表明，英夫利昔单抗可使约20%的患者实现缓解并停用类固醇。然而，感染和癌症的长期风险意味着英夫利昔单抗应仅用于病情最严重的患者。
Zotero 插件